ASXL1 and acute myeloid leukemia: A comprehensive clinicogenomic analysis was conducted on 451 AML patients with ASXL1 or KRAS mutations from the discovery cohort (n = 394) and the independent validation cohort (n = 57) to assess the correlation between molecular profiles and clinical outcomes.<h4>Results</h4>The KRAS mutation was observed in 22 (9.9%) AML cases with the ASXL1 mutation.